This clinical trial is focused on studying a condition called Multiple Myeloma, which is a type of cancer that affects plasma cells in the bone marrow. The study is testing different treatments to see how effective and safe they are for people whose disease has returned or has not responded to previous treatments. The treatments being tested include a new medication called Elranatamab (also known by its code name PF-06863135), which is given as an injection. The study will also look at the combination of Elranatamab with another medication called Daratumumab, and compare it to a combination of Daratumumab with two other drugs, Pomalidomide and Dexamethasone.
The purpose of the study is to find out which treatment works best for patients with relapsed or refractory Multiple Myeloma. Participants in the study will be randomly assigned to one of three groups. One group will receive Elranatamab alone, another group will receive Elranatamab combined with Daratumumab, and the third group will receive Daratumumab combined with Pomalidomide and Dexamethasone. The study will monitor the participants over a period of time to see how their disease responds to the treatment and to check for any side effects.
Throughout the study, participants will receive regular check-ups and tests to monitor their health and the progress of their treatment. The study aims to provide valuable information that could help improve treatment options for people with Multiple Myeloma in the future. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.
Austria 
Belgium 
Czechia 
Finland 
France 
Germany 
Greece 
Italy 
Norway 
Poland 
Spain 
Sweden 
The Netherlands 